Humana Inc. stock underperforms Friday when compared to competitors

Humana (HUM) agreed to a $2.8 bn deal with BlackRock, restructuring ownership of 150 CenterWell clinics. BlackRock acquires WCAS's majority stake, with Humana retaining minority ownership. The deal reduces Humana's balance sheet obligations. Humana's Medicare Advantage star ratings improved, potentially increasing 2028 bonus payments to $4.8 bn, per Evercore ISI. S&P affirmed Humana's BBB rating but maintained a negative outlook.

Humana announced that BlackRock's HPS Investment Partners will acquire Welsh Carson's stake in about 150 CenterWell clinics, valued at $2.8B. The deal, expected to close in Q4 2026, will make BlackRock the majority owner, with CenterWell retaining a minority stake and operational control. Humana stated patient care will remain unchanged, and the deal is not expected to materially affect its 2026 earnings guidance.

Humana and BlackRock's HPS Investment Partners will form a joint venture to operate and expand CenterWell clinics, with BlackRock acquiring WCAS's stake for $2.8B. The deal aims to provide growth capital and lower costs for Humana, with no disruption to patient care. Humana may repurchase clinics starting 2028. The transaction is expected to close in Q4 2026, with no impact on 2026 earnings guidance.

Humana (NYSE: HUM) announced a joint venture with BlackRock to manage 150 CenterWell clinics, while Village Medical divested 27 clinics to Harbor Health. These moves suggest a shift in the senior-focused primary care industry, with changes in ownership and financing strategies. Humana's deal includes a $2.8 billion equity acquisition and potential clinic purchases by CenterWell starting in 2028.

Humana (HUM) is forming a joint venture with BlackRock to own 150 CenterWell clinics, valued at $2.8B. BlackRock will hold majority ownership, with Humana retaining minority. The deal, expected to close in Q4 2026, will reduce Humana's liabilities and support clinic expansion. Humana's 2026 earnings guidance remains at least $9 per share.

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.